Polysorbate 20
CAS 9005-64-5
Polysorbate 20 (CAS 9005-64-5) is a pharmaceutical compound with 0 bioactivity targets and 103 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Polysorbate 20 is linked to DTXSID3031949 in DSSTox identifiers.
View industrial chemical data →Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| POLYSORBATE 20 | 8559 | SU | MTHSPL |
| Polysorbate 20 | 8559 | SU | MTHSPL |
| polysorbate 20 | 8559 | SU | MTHSPL |
| polysorbate 20 | 8559 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Polysorbate 20 used for in pharmaceutical contexts?
Polysorbate 20 (CAS 9005-64-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Polysorbate 20?
Polysorbate 20 has 103 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Balance disorder, Bladder disorder, Blood calcium decreased, Cognitive disorder, Constipation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Polysorbate 20 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Polysorbate 20 with EU status "permitted".
What clinical phase is Polysorbate 20 in?
No phase 1-4 clinical development badge is rendered for Polysorbate 20 because the matched compound identifier rows do not contain a max-phase value.